Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis (NCT05138133)

🧪 Interventions in This Study

• Anifrolumab (DRUG)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (164 Sites)

Showing the first 25 of 164 sites.

• Research Site — Glendale, Arizona
• Research Site — La Palma, California
• Research Site — Los Angeles, California
• Research Site — Upland, California
• Research Site — Plantation, Florida
• Research Site — Atlanta, Georgia
• Research Site — Louisville, Kentucky
• Research Site — Summit, New Jersey
• Research Site — Manhasset, New York
• Research Site — New York, New York
• Research Site — Winston-Salem, North Carolina
• Research Site — Middleburg Heights, Ohio
• Research Site — Colleyville, Texas
• Research Site — Edinburg, Texas
• Research Site — El Paso, Texas
• Research Site — Houston, Texas
• Research Site — CABA,
• Research Site — Ciudad de Buenos Aires,
• Research Site — La Plata,
• Research Site — Rosario,
• Research Site — San Juan,
• Research Site — Brussels,
• Research Site — Leuven,
• Research Site — Liège,
• Research Site — Belo Horizonte,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Lupus Nephritis

• KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis — Palo Alto, California
• Daratumumab to Treat Active Lupus Nephritis — Rochester, Minnesota
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis — Birmingham, Alabama
• An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases — Phoenix, Arizona
• Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis — Birmingham, Alabama

Explore by condition: All Lupus Nephritis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.